Innovative regimens in the therapy of NSCLC

During the last decades our view on registered drugs widen the registration issues. In the article authors want to discuss innovative approaches to checkpoint inhibitors dosing, the rational for combinations of targeted agents with cytotoxic drugs, unregistered in RECIST classification antitumor effect of immunotherapy, and the possibility of drug sequencing. Authors idea is that the data generated during recent period might be of great importance not only for clinical optimization, but also might influence the deeper understanding of tumor process